Diffuse Large B Cell Lymphoma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

80 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diffuse Large B Cell Lymphoma
2009-010700-28: GRANITE-1 - Transmission of specific immune cells from healthy donors for cancer patients with fever, who lack these cells

Ongoing
3
200
Europe
Granulocyte-Transfusion, Granocyte-13, Neupogen 30, Neupogen 48, Granocyte 34, no product code available, Infusion, Powder and solvent for solution for injection, Solution for injection, GRANOCYTE 13, NEUPOGEN 30, NEUPOGEN 48, GRANOCYTE 34
University of Cologne, Deutsche Forschungsgesellschaft (DFG)
Febrile neutropenia due to chemotherapy for the following diseases:C92.0- - Acute myeloid leukemiaC91.0- - Acute lymphoblastic leukemiaC92.1- - Chronic myeloid leukemiaC91.1- - Chronic lymphoblastical leukemiaD46.9 - Myelodysplastic syndromeD47.1 - Chronic myeloproliferative diseaseC82.- - Follicular/nodular NHLD83.- - Diffuse Non-Hodgkin's Lymphoma (NHL)C84.4 - Peripheral T-Cell NHLC90.0- - Multiple myelomaC81.9 - Hodgkin's lymphoma (HL), Patients with cancer of the blood or the immunesystem who have a weak immunesystem due to chemotherapy,who develope fever during the time of a weak immunesystem can take part in this study., Diseases [C] - Cancer [C04]
 
 
ACTRN12611000085976: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

Active, not recruiting
3
80
 
Australasian Leukaemia and Lymphoma Group, GELA, Australasian Leukaemia and Lymphoma Group, Celgene Global
Diffuse large B cell lymphoma (DLBCL) in elderly patients
 
 
2006-005174-42: Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma

Ongoing
3
460
Europe
prednisone, cyclophosphamide, doxorubicin, vincristine, Neulasta, Neulasta, Mabthera, Neulasta, Mabthera
HOVON Foundation, HOVON Foundation, Roche Nederland B.V.,
diffuse large B-cell lymphoma
 
 
2009-016136-12: PET-RIMCEB:Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patientsA phase III studyA randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas+A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas

Ongoing
3
150
Europe
Mabthera, Mabthera, Mabthera
Czech Lymphoma Research Organization s.r.o. (CLRO)
Prognosis of high-risk patients with diffuse large B-cell lymphoma is still less then optimal. According to revised Int. Prognostic Index, patients with 3-5 adverse prognostic factors have only about 50% chance of survival in 4 years. In theory, there are 3 possibilities how to improve prognosis of patients with poor-risk DLBCL: intensification of induction therapy, high-dose consolidation treatment with autologous stem cell transplant or combination of both methods.
 
 
2013-005506-56: The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patients

Ongoing
3
30
Europe, RoW
MabionCD20 (biosimilar to rituximab), MabThera, CD20, MabThera, MabThera
MABION SA, Mabion SA, Mabion SA
CD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance at least 6 months
 
 
ChiCTR-TRC-08000243: A Prospective, Multicenter, Randomized Phase III Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients

Recruiting
3
732
 
CHOP combined with Rituximab regimen (R-CHOP21) ;Biweekly CHOP combined with Rituximab regimen (R-CHOP14) ;Biweekly CHOP regimen (CHOP14)
Sun Yat-sen University; Level of the institution：, Sun Yat-sen University
untreated CD20 positive difussed large B cell lymphoma adults
 
 
2017-004618-24: Evaluation of the protective effect on the heart of a betablocker drug, nebivolol, in patients with breast cancer or diffuse B-cell lymphoma for which anthracyclinic chemotherapy has been planned Valutazione dell'effetto di protezione sul cuore di un farmaco betabloccante, nebivololo, in pazienti con tumore della mammella o linfoma diffuso a cellule B per i quali è stata pianificata chemioterapia con antracicline

Ongoing
3
80
Europe
NEBIVOLOLO, NEBIVOLOLO, Capsule, hard, NEBIVOLOLO DOC GENERICI - 5 MG COMPRESSE "" 28 COMPRESSE IN BLISTER PVDC/PVC/AL
IRCCS ISTITUTO CLINICO HUMANITAS
To prevent cardiotoxicity of chemotherapeutic agents (anthracyclines) Prevenzione della cardiotossicità da chemioterapia (antracicline), To prevent cardiotoxicity of chemotherapeutic agents (anthracyclines) Prevenire la cardiotossicità da chemioterapia (antracicline), Diseases [C] - Cardiovascular Diseases [C14]
 
 
ChiCTR-TRC-11001687: A prospective, multicenter randomized phase III clinical trial of intensified chemotherapy in improving the treatment efficacy of patient with diffuse large B-cell lymphoma

Recruiting
3
454
 
R-CHOP repeated in 21 days ;R-CHOP repeated in 14 days
SUN YAT-SEN UNIVERSITY CANCER CENTER; SUN YAT-SEN UNIVERSITY CANCER CENTER, SUN YAT-SEN UNIVERSITY CANCER CENTER/SUN YAT-SEN UNIVERSITY
Diffuse large B-cell Lymphoma
 
 
NCT02449278: The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Recruiting
3
120
RoW
Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Wuhan University
Diffuse Large B-cell Lymphoma
10/19
10/25
NCT02449265: Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Recruiting
3
160
RoW
Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Wuhan University
Diffuse Large B-cell Lymphoma
10/19
10/25
NCT03016000: Thalidomide Maintenance Treatment in DLBCL

Recruiting
3
226
RoW
Thalidomide, Thalomid, Observation
Nanfang Hospital of Southern Medical University
Lymphoma, Large B-Cell, Diffuse
12/19
12/23
NCT02842931: R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Recruiting
3
300
RoW
R-DA-EPOCH-21, R-DA-EPOCH-21 + auto-SCT, R-mNHL-BFM-90, R-mNHL-BFM-90 + auto-SCT
National Research Center for Hematology, Russia, National Research Center for Hematology
Diffuse Large B-Cell Lymphoma
02/20
02/23
NCT03650933: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Recruiting
3
360
RoW
G-CHOP, R-CHOP
Nanjing Yoko Biomedical Co., Ltd.
Diffuse Large B-Cell Lymphoma, Unspecified Site
08/22
12/25
2019-001755-39: A Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

Ongoing
3
600
Europe
acalabrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, ACP-196, L01X C02, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection, Solution for infusion, Solution for injection, Tablet, MabThera 500 mg concentrate for solution for infusion, Endoxan 500 mg Powder for solution for injection, Ribodoxo 2 mg/ml solution for infusion, Vincristinesulfat-TEVA 1 mg/ml Injectable solution, Prednisone HEXAL 20 mg tablets
Acerta Pharma B.V. (A Member of the AstraZeneca Group), ACERTA PHARMA BV, AstraZeneca
Diffuse large B-cell lymphoma, A type of non-Hodgkin lymphoma that develops when B-cells become abnormal., Diseases [C] - Cancer [C04]
 
 
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5)

Ongoing
3
350
Europe, RoW
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml
ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04]
 
 
2018-002115-96: Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and total drug dose in comparison to the standard induction therapy and both treatments followed by a high dose therapy with autologous stem cell transplantation. The therapy is for patients with newly diagnosed primary lymphoma of the central nervous system. Optimierung einer in Dauer und Gesamtdosis abgeschwächten, einleitenden Therapie mit MATRix, einer Medikamentenkombination, bestehend aus Methotrexat, ARA-C, Thiotepa und Rituximab im Vergleich zur Standard Einleitungstherapie; beiden folgt eine Hochdosistherapie und autologe Stammzelltransplantation. Die Behandlung ist für Patienten mit neu diagnostizierten primären Lymphomen des zentralen Nervensystems.

Not yet recruiting
3
326
Europe
Rituximab, Methotrexate, Cytarabine, Thiotepa, Carmustine, Busulfan, [NA], Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Powder and solvent for solution for infusion
Klinikum Stuttgart, Landeshauptstadt Stuttgart gKAöR, CITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART, BMBF Federal Ministry of Education and Research, Dipartimento Federale della Formazione e della Ricerca (BMBF/DLR)
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchyma, leptomeninges, eyes or spinal cord. It accounts for 4 to 6% of all Non-Hodgkin’s lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 years, particularly in immunocompetent individuals.With a median survival of 3 months in untreated individuals, prognosis of PCNSL resembles that of systemic high-grade NHL. Primäres diffuses großes B-Zell-Lymphom (DLBCL) des zentralen Nervensystems ist eine seltene Erkrankung der zerebalen Parenchyma, Leptomeninges, der Augen oder des Rückenmarks. Sie macht 4-6% aller Non-Hodgkin Lymphome (NHL) und 3-4% aller primären Hirntumore aus. Die Inzidenz von PZNSL ist in den vergangenen 30 Jahren angestiegen vor allem bei immunkompeten Patienten. Die durchschnittliche Überlebensrate bei unbehandelten Patienten liegt bei 3 Monaten., Primary diffuse large B-cell lymphoma of central nervous system, a rare disorder confined to the brain and spinal cord. The disease may be fatal within a short period of time when remained untreated. ZNSNHL ist eine seltene Erkrankung des lymphat. Systems im Bereich Gehirn/Rückenmark. Es handelt sich dabei um bösartiger Immunzellen. Die Krankheit kann unbehandelt in kurzer Zeit zum Tode führen., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-002962-10: An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system.

Not yet recruiting
3
334
Europe
Polivy, Mabthera, Ifosfamide, Carboplatin, Etoposide, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Polivy, MABTHERA®
GWT-TUD GmbH, F. Hoffmann-La Roche Ltd
primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), patients whose cancer of the lymph nodes has returned or not responded to treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
EVAPOR, NCT04214444: Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab

Recruiting
3
36
Europe
Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
University Hospital, Tours, Hôpital Cochin
Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
07/21
07/22
ChiCTR1900022909: A single-institution, randomized, phase III study for Lenalidomide plus ICE versus ICE in relapsed or refractory non - GCB diffuse large B cell lymphoma

Not yet recruiting
3
100
 
R-ICE ;ICE
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing
diffuse large B cell lymphoma
 
 
IELSG37, NCT01599559: Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
3
540
Europe, Canada, US, RoW
observation, 3D-Conformal Radiotherapy (3D-CRT)
International Extranodal Lymphoma Study Group (IELSG)
Primary Mediastinal B-cell Lymphoma
06/22
12/29
DOBL, NCT02964858: Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Recruiting
3
840
RoW
Standard Arm, Experimental Arm
Tata Memorial Hospital
NonHodgkin Lymphoma
11/22
06/23
ZUMA-7, NCT03391466 / 2017-002261-22: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Checkmark Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
Checkmark Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
Checkmark Data from ZUMA-7 trial for 2L DLBCL at ASCO 2022
More
Active, not recruiting
3
359
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, KTE-C19, axi-cel, Yescarta ®, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders., Cyclophosphamide, Fludarabine
Kite, A Gilead Company
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
03/21
10/24
CONTROL, NCT05728632: Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines

Active, not recruiting
3
80
Europe
Nebivolol, Lobivon, Placebo
Giulio Stefanini, Agenzia Italiana del Farmaco
Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction, Chemotherapy Effect
02/23
02/23
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT04799314: PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Not yet recruiting
3
132
RoW
PD-1 Inhibitor Tislelizumab maintenance therapy
Ruijin Hospital
Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
04/23
04/24
2020-001181-10: Age-adapted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy and maintenance therapy in fit elderly patients* with initial diagnosis of primary cerebral lymphoma. Altersadaptierte Hochdosis-Chemotherapie gefolgt von autologer Stammzelltransplantation oder konventioneller Chemotherapie und Erhaltungstherapie bei fitten älteren Patient*innen mit Erstdiagnose eines primären zerebralen Lymphoms

Not yet recruiting
3
310
Europe
Rituximab, Methotrexate, Cytarabine, Thiotepa, Busulfan, Procarbazine, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Capsule, hard
Medical Center - University of Freiburg, BMBF Federal Ministry of Education and Research
Primary diffuse large B-cell lymphoma of the central nervous system(PCNSL) is a rare lymphoma affecting only the central nervous systemcompartment. PCNSL patients are typically 60 years or older and havepoor prognoses. Considering the poor prognosis of this patientpopulation, this randomised phase III trial proposal is of great clinicalimportance to provide patients optimal treatment. Das primäre diffuse großzellige B-Zell-Lymphom des zentralenNervensystems (PCNSL) ist ein seltenes Lymphom, das nur das zentraleNervensystem betrifft. PCNSL-Patienten sind in der Regel 60 Jahre oderälter. In Anbetracht der schlechten Prognose dieser Patientengruppe istdiese randomisierte Phase-III-Studie von großer klinischer Bedeutung,um den Patienten eine optimale Behandlung zu bieten., The primary lymphoma of the central nervous system is a rare disease,which occurs only in the central nervous system and more often amongelderly patient, who have a poor prognosis. Das primäres Lymphom des zentralen Nervensystems ist ein seltenesLymphom, das nur das zentrale Nervensystem betrifft und bei Patientenab 60 Jahren öfter auftritt und eine schlechte Prognose hat., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04789434: PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Recruiting
3
94
RoW
PD-1 Inhibitor Tislelizumab maintenance therapy
Ruijin Hospital
Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
07/23
07/24
DEB, NCT04231448: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruiting
3
423
RoW
R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo
Chipscreen Biosciences, Ltd.
Diffuse Large B-cell Lymphoma
07/23
03/25
NCT03213977: R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

Active, not recruiting
3
475
RoW
R-DA-EPOCH, R-CEOP90
Fujian Medical University
Diffuse Large B-cell Lymphoma
07/23
07/24
CALVI, NCT03800095: Early Palliative Care for Patients With Haematological Malignancies

Recruiting
3
140
Europe
Early palliative care integration
University Hospital, Clermont-Ferrand, Fondation Apicil, Association des foulées de la Haute Lozère, Association CEMSBM, Connaître et Combattre les Myélodysplasies
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large B Cell Lymphoma, Palliative Care
08/23
12/23
ChiCTR2000040602: Multicenter, randomized, double-blind, and parallel active controlled trial for comparing the efficacy and safety of Haizheng recombinant human - mouse chimeric anti-CD20 monoclonal antibody injection (HS006) combined with CHOP(Hi-chop) and Rituximab combined with CHOP(R-chop) in initial treatment for patients with diffuse large B

Recruiting
3
480
 
Hi-chop ;R-chop
Center for Cancer Prevention and Treatment of Sun Yat-Sen University; Zhejiang Hisun Pharmaceutical Co., Ltd, Zhejiang Hisun Pharmaceutical Co., Ltd.
Diffuse large B cell lymphoma
 
 
NCT05040906: A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Recruiting
3
416
RoW
H02+CHOP, Rituxan +CHOP
Shandong New Time Pharmaceutical Co., LTD
Recruiting
10/23
12/23
NCT05020392: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Recruiting
3
24
RoW
BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Wuhan Union Hospital, China, Wuhan Si'an Medical Technology Co., Ltd
Diffuse Large B Cell Lymphoma, Burkitt Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
10/23
10/24
NCT04094311: Study of Out of Specification for Tisagenlecleucel

Recruiting
3
200
Canada, Japan
CTL019, Tisagenlecleucel
Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
04/25
04/25
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
160
RoW
Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX
Shandong Provincial Hospital
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma
12/23
12/24
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
130
RoW
Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
Shandong Provincial Hospital
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma
12/23
12/24
NCT06186986: CD30 Imaging in Diffuse Large B-cell Lymphoma

Not yet recruiting
3
20
NA
Brentuximab vedotin, 89ZR-Brentuximab
University Medical Center Groningen, Takeda
Diffuse Large B-cell-lymphoma
01/25
01/26
NCT02443077: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
3
302
US, RoW
Autologous Bone Marrow Transplantation, ABMT, Autologous Blood and Marrow Transplantation, Autologous Bone Marrow Transplant, Autologous Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Pharmacogenomic Study, PHARMACOGENOMIC, Placebo Administration
National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
05/25
05/25
HO170DLBCL, NCT06220032: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Not yet recruiting
3
324
Europe
Dexrazoxane, Cardioxane, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Lenalidomide, Revlimid, Pegfilgrastim, Pegfilgastim
Stichting Hemato-Oncologie voor Volwassenen Nederland, UMC Utrecht, Amsterdam University Medical Centers, The Dutch Network for Cardiovascular Research (WCN)
DLBCL - Diffuse Large B Cell Lymphoma
12/28
12/28
GOLSEEK-1, NCT06356129: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Recruiting
3
850
Europe, Canada, Japan, US, RoW
Golcadomide, BMS-986369, CC-99282, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Celgene
Large B-cell Lymphoma
08/28
11/29
POLARIX, NCT03274492 / 2017-002023-21: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Checkmark Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Checkmark Presentation of POLARIX trial in 1L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Presentation of POLARIX trial in 1L DLBCL at ASH 2022
Checkmark Exploratory subgroup analyses from Asian population group of POLARIX trial for DLBCL at EHA 2022
More
Active, not recruiting
3
1000
Europe, Canada, Japan, US, RoW
Polatuzumab Vedotin, DCDS4501A; anti-CD79b-VC-MMAE, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
06/24
06/24
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting
3
150
RoW
Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma (DLBCL)
07/24
12/25
POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
3
270
Europe, Canada, US, RoW
Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
09/24
03/25
Pola-R-ICE, NCT04833114: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide () Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
3
334
Europe
Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide
GWT-TUD GmbH, Hoffmann-La Roche
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
10/24
12/25
EPCORE DLBCL-1, NCT04628494 / 2020-003016-27: A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL

Hourglass Jan 2023 - Dec 2023 : Interim data from EPCORE DLBCL-1 trial for 3L DLBCL
Active, not recruiting
3
552
Europe, Canada, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, Investigator's Choice Chemotherapy, BR or R-GemOx
Genmab, AbbVie
Diffuse Large B-cell Lymphoma
12/24
04/28
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL
Recruiting
3
270
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
04/25
04/25
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Recruiting
3
222
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
05/25
11/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
MorphoSys AG
Diffuse Large B-cell Lymphoma
06/25
05/26
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Recruiting
3
350
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
PHARAOM, NCT04670029: Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line

Recruiting
3
186
Europe
Adapted physical activity
Weprom
Diffuse Large B Cell Lymphoma
08/25
02/29
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
NCT05018520: The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Recruiting
3
800
RoW
Six Courses of R-CHOP Plus Two Courses of Rituximab, Four Courses of R-CHOP Plus Four Courses of Rituximab
Ruijin Hospital
Diffuse Large B Cell Lymphoma
09/25
09/25
NHL-011, NCT05054426: Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL

Recruiting
3
488
RoW
Methotrexate
Peking Union Medical College Hospital
Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
10/25
10/25
firmMIND, NCT05429268 / 2021-006049-36: Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
81
Europe, RoW
Tafasitamab, INCMOR00208, MOR00208, Lenalidomide
Incyte Corporation
Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
12/25
12/26
PEARL, NCT05179733: The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Recruiting
3
280
RoW
six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP
Ruijin Hospital, Wuhan Union Hospital, China, Ningbo No. 1 Hospital, National Naval Medical Center, Shanghai Fengxian District Central Hospital, YANCHENG NO.1 PEOPLE'S HOSPITAL, The First Affiliated Hospital of Nanchang University, Affiliated Hospital of Nantong University, Wuxi Branch of Ruijin Hospital, Sir Run Run Shaw Hospital, Northern Jiangsu Province People's Hospital, The First People's Hospital of Changde City, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changzhou No.2 People's Hospital, The Affiliated Hospital of Xuzhou Medical University, Huai'an First People's Hospital, Taizhou Hospital, The First People's Hospital of Kunshan, First Affiliated Hospital of Fujian Medical University, Huadong Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shandong Provincial Hospital, HARBIN THE FIRST HOSPITAL, The First Hospital of Jilin University, Hunan Cancer Hospital, Qilu Hospital of Shandong University, THE FIRST AFFILIATED HOSPITAL, The Second Affiliated Hospital of Dalian Medical University, SUZHOU HONGCI HEMATOLOGY HOSPITAL
Diffuse Large B-Cell Lymphoma
12/25
12/25
NCT05466318: ChiCGB vs BEAM in High-risk or R/R Lymphomas

Recruiting
3
306
RoW
Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant
Sichuan University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
12/25
12/25
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
02/26
02/26
NCT05351346: Genotype-guided Treatment in DLBCL

Recruiting
3
1100
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Orelabrutinib, Lenalidomide, Decitabine
Ruijin Hospital, West China Hospital, Sichuan, Qilu Hospital of Shandong University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Wuhan Union Hospital, China, The Second Hospital of Anhui Medical University, Zhongda Hospital, The First Affiliated Hospital of Soochow University, China-Japan Friendship Hospital, Tongji Hospital, Beijing Hospital, The Second Affiliated Hospital of Dalian Medical University, Zhujiang Hospital, The First Affiliated Hospital of Anhui Medical University North District, Hunan Cancer Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Cancer Hospital Affiliated to Xinjiang Medical University, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Nanchang University, LanZhou University, Central South University, The Affiliated Hospital of Xuzhou Medical University, Yunnan Cancer Hospital, Henan Cancer Hospital, Fujian Medical University Union Hospital, The First Hospital of Jilin University, The First Affiliated Hospital of Anhui Medical University, Gansu Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital Xi'an Jiaotong University, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shandong Cancer Hospital and Institute, Affiliated Cancer Hospital of Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Fudan University, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Pekcing Union Medical College, Affiliated Hospital of Nantong University, Yunnan First People's Hospital, Shanxi Province Cancer Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Beijing Tongren Hospital, First Affiliated Hospital of Harbin Medical University, Ruian People's Hospital, Harbin Institute of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Affiliated Hospital of Guilin Medical College, Air Force Medical Center. PLA, The Affiliated Zhongshan Hospital of Dalian University, Yantai Yuhuangding Hospital, The First Affiliated Hospital of Zhengzhou University, Peking University Third Hospital
Diffuse Large B Cell Lymphoma
06/26
06/26
SKYGLO, NCT06047080: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting
3
1130
Europe, Canada, Japan, US, RoW
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Large B-Cell Lymphoma
06/26
02/29
ChiCTR1800018708: A prospective, phase III, multicenter, randomized controlled trial for short-course chemotherapy in the treatment of localised low risk diffuse large b-cell lymphoma

Recruiting
3
250
 
RCHOP chemo for 4 doses ;RCHOP chemo for 6 doses
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, The foundation of 5010 Clinical Trials of Sun Yat-sen University
diffuse large b-cell lymphoma
 
 
ChiCTR1800018720: A prospective, phase III, multicenter, randomized study for sequential chemotherapy (RCHOP/RIMVP16/RDHAP, CID-RATT) of middle - and high-risk diffuse large B-cell lymphoma

Not yet recruiting
3
364
 
Receive sequential chemotherapy (RCHOP/RIMVP16/RDHAP,CID-RATT) for 6 cycles ;Receive 6 cycles RCHOP chemo
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, The foundation of 5010 Clinical Trials of Sun Yat-sen University
diffuse large b-cell lymphoma
 
 
NCT05431179 / 2022-001547-25: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Withdrawn
3
365
NA
Zilovertamab, Cirmtuzumab, UC961, Ibrutinib, Imbruvica, Placebo
Oncternal Therapeutics, Inc, Pharmacyclics LLC.
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
11/26
12/26
NCT01804686 / 2012-004225-24: A Long-term Extension Study of PCI-32765 (Ibrutinib)

Enrolling by invitation
3
700
Europe, Canada, Japan, US, RoW
Ibrutinib, PCI-32765
Janssen Research & Development, LLC, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
12/26
01/27
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/27
12/29
ESCALADE, NCT04529772 / 2019-001755-39: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L DLBCL (based on ESCALADE trial)
Calendar Jan 2024 - Dec 2024: Data from ESCALADE trial in combination with R-CHOP for 1L DLBCL
Active, not recruiting
3
611
Europe, Canada, Japan, US, RoW
acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
Acerta Pharma BV, AstraZeneca
Diffuse Large B-Cell Lymphoma
02/27
02/27
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting
3
330
Europe
R-miniCHOP + Acalabrutinib, R-miniCHOP
Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
04/28
12/28
OLYMPIA-3, NCT06091865: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Recruiting
3
904
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prednisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Diffuse Large B-cell Lymphoma (DLBCL)
09/28
09/28
NCT04759586: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Recruiting
3
244
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Etoposide Phosphate, Etopophos, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Lumbar Puncture, LP, Spinal Tap, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
09/27
09/27
ZUMA-23, NCT05605899: Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Hourglass Jul 2022 - Dec 2022 : First-patient-in of ZUMA-23 trial for 1L high-risk LBCL
Recruiting
3
300
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Axi-cel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
Kite, A Gilead Company
High-risk Large B-cell Lymphoma (LBCL)
03/31
03/31
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20
2021-003313-18: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.

Ongoing
2/3
420
Europe
Zilovertamab Vedotin, Gemcitabine hydrochloride, Bendamustine Chydrochloride, Oxaliplatin, MK-2140, Solution for injection, Powder for solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Gemcitabine SUN, Bendamustin medac, Oxaliplatin AqVida, MabThera 100mg, MabThera 500 mg
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin's lymphoma, in patients who failed prior therapies), Diseases [C] - Cancer [C04]
 
 
Soh-Med-24-03--06PD, NCT06355401: Maintenance Hormonal Therapy and DLBCL

Not yet recruiting
2/3
100
NA
Tamoxifen 20mg
Sohag University
Diffuse Large B Cell Lymphoma
03/26
03/29
B-MIND, NCT02763319 / 2014-004689-11: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Hourglass Jan 2022 - Mar 2022 : From B-MIND trial in combination with bendamustine for r/r DLBCL
Checkmark Data from B-MIND trial in combination with bendamustine for r/r DLBCL
Aug 2019 - Aug 2019: Data from B-MIND trial in combination with bendamustine for r/r DLBCL
Active, not recruiting
2/3
450
Europe, Canada, US, RoW
Rituximab (RTX), Rituxan, Mab Thera, Tafasitamab, Bendamustine (BEN), Levact/Treanda
MorphoSys AG, ICON Clinical Research
Diffuse Large B-cell Lymphoma
06/24
06/24
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT04799275: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Recruiting
2/3
422
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Oral Azacitidine, Azacitidine Oral, CC-486, Onureg, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
03/26
03/26
waveLINE-003, NCT05139017 / 2021-003313-18: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
2/3
260
Europe, Canada, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, Rituxan®/mabthera, Truxima® (rituximab-abbs), RUXIENCE®), Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®, Bendamustine, Bendeka®, Treanda®, Belrapzo®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
DLBCL, Diffuse Large B-Cell Lymphoma
06/27
06/27
NCT05664217: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Recruiting
2/3
400
US
NKTR-255 at 1.5 µg/kg, Polymer-conjugated interleukin (IL)-15 Receptor Agonist, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
Nektar Therapeutics
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
01/27
01/29
A051701, NCT03984448: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Active, not recruiting
2/3
363
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Lumbar Puncture, LP, Spinal Tap, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/28
04/28

Download Options